

## ORIGINAL ARTICLE

# Loss of retinal ganglion cells in a new genetic mouse model for primary open-angle glaucoma

Sabrina Reinehr<sup>1</sup> | Dennis Koch<sup>1</sup> | Maximilian Weiss<sup>1</sup> | Franziska Froemel<sup>2</sup> |  
Christina Voss<sup>1</sup> | H. Burkhard Dick<sup>1</sup> | Rudolf Fuchshofer<sup>2\*</sup> | Stephanie C. Joachim<sup>1\*</sup> 

<sup>1</sup>Experimental Eye Research  
Institute, University Eye Hospital, Ruhr-  
University Bochum, Bochum, Germany

<sup>2</sup>Institute of Human Anatomy and  
Embryology, University Regensburg,  
Regensburg, Germany

## Correspondence

Stephanie C. Joachim, Experimental Eye  
Research Institute, University Eye Hospital,  
Ruhr-University Bochum, In der Schornau  
23-25, 44892 Bochum, Germany.  
Email: stephanie.joachim@rub.de

## Funding information

FoRUM (Ruhr-University Bochum);  
Deutsche Forschungsgemeinschaft, Grant/  
Award Number: FU734/4-1; Ernst und Berta  
Grimmke foundation

## Abstract

Primary open-angle glaucoma (POAG) is one of the most common causes for blindness worldwide. Although an elevated intraocular pressure (IOP) is the main risk factor, the exact pathology remained indistinguishable. Therefore, it is necessary to have appropriate models to investigate these mechanisms. Here, we analysed a transgenic glaucoma mouse model ( $\beta$ B1-CTGF) to elucidate new possible mechanisms of the disease. Therefore, IOP was measured in  $\beta$ B1-CTGF and wildtype mice at 5, 10 and 15 weeks of age. At 5 and 10 weeks, the IOP in both groups were comparable ( $P > 0.05$ ). After 15 weeks, a significant elevated IOP was measured in  $\beta$ B1-CTGF mice ( $P < 0.001$ ). At 15 weeks, electroretinogram measurements were performed and both the a- and b-wave amplitudes were significantly decreased in  $\beta$ B1-CTGF retinae (both  $P < 0.01$ ). Significantly fewer Brn-3a<sup>+</sup> retinal ganglion cells (RGCs) were observed in the  $\beta$ B1-CTGF group on flatmounts ( $P = 0.02$ ), cross-sections ( $P < 0.001$ ) and also via quantitative real-time PCR ( $P = 0.02$ ). Additionally, significantly more cleaved caspase 3<sup>+</sup> RGCs were seen in the  $\beta$ B1-CTGF group ( $P = 0.002$ ). Furthermore, a decrease in recoverin<sup>+</sup> cells was observable in the  $\beta$ B1-CTGF animals ( $P = 0.004$ ). Accordingly, a significant down-regulation of *Recoverin* mRNA levels were noted ( $P < 0.001$ ). *Gfap* expression, on the other hand, was higher in  $\beta$ B1-CTGF retinae ( $P = 0.023$ ). Additionally, more glutamine synthetase signal was noted ( $P = 0.04$ ). Although no alterations were observed regarding photoreceptors via immunohistology, a significant decrease of *Rhodopsin* ( $P = 0.003$ ) and *Opsin* mRNA ( $P = 0.03$ ) was noted. We therefore assume that the  $\beta$ B1-CTGF mouse could serve as an excellent model for better understanding the pathomechanisms in POAG.

## KEYWORDS

electroretinogram, primary open-angle glaucoma, retinal ganglion cells,  $\beta$ B1-CTGF

\*Equally contributing senior authors.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

## 1 | INTRODUCTION

An elevated intraocular pressure (IOP) is considered the main risk factor for glaucoma.<sup>1</sup> This neurodegenerative disease is defined as an optic neuropathy with changes at the optic nerve head and progressive retinal ganglion cell (RGC) death followed by visual field loss.<sup>1</sup> Glaucoma usually remains asymptomatic until late-stage disease, when about 30% of the RGCs are lost. Then, abnormalities in automated visual field testing can be noted.<sup>2</sup> The current therapies aim to lower the IOP. However, these treatments can only decelerate the progression of the RGC death and not recover cells which were already damaged. Therefore, it will be beneficial to detect glaucoma at very early stages to begin therapies as soon as possible. To acquire this goal, an adequate animal model for primary open-angle glaucoma (POAG) is required. Several ocular hypertension (OHT) models are available, but most of them elevate the IOP through surgical interventions.<sup>3-6</sup> These manipulations could lead to local inflammations and therefore would be detrimental for analyses of the immune response. As genetic model, the DBA2/J mouse is used most of the time.<sup>7-9</sup> However, this model more reflects a pigment dispersion glaucoma.<sup>7,10,11</sup> A new transgenic model for POAG is the connective tissue growth factor ( $\beta$ B1-CTGF) mouse. Here, the lens-specific overexpression of CTGF leads to changes of the extracellular matrix and of the cytoskeleton in the trabecular meshwork followed by an increase of the IOP. Furthermore, a progressive loss of axons in the  $\beta$ B1-CTGF optic nerves was reported after 4-12 weeks.<sup>12</sup> In the study presented here, we aimed to investigate functional and morphological changes in the retina of the  $\beta$ B1-CTGF mice in comparison to IOP changes for the first time. We therefore performed functional analyses of the retina. Retinal samples were investigated regarding different cell types including RGCs, bipolar cells, macroglia and photoreceptors. We could demonstrate that an elevated IOP is associated with the apoptotic loss of RGCs in the transgenic  $\beta$ B1-CTGF mouse model.

## 2 | METHODS

### 2.1 | Animals

Transgenic  $\beta$ B1-Crystallin-CTGF mice were generated as described in detail previously.<sup>12</sup> In brief, for generation of the  $\beta$ B1-Crystallin-CTGF construct, the murine cDNA of CTGF was cloned in a plasmid containing the  $\beta$ B1-Crystallin promoter and the simian virus 40 (SV40) polyA signal region and the SV40 small-T intron to obtain plasmid  $\beta$ B1-Crystallin-CTGF. Constructs for microinjection were released from plasmid  $\beta$ B1-CTGF by digestion and transgenic mice were generated in a FVB/N background as described previously.<sup>13</sup> For this study, the mice were backcrossed into a CD1 background over eight generations. Therefore both, wildtype (WT) and  $\beta$ B1-CTGF animals, had a CD1 background. All animals were bred in-house at the animal facility at the Ruhr-University Bochum. WT CD1 mice for breeding were obtained from Charles River.  $\beta$ B1-CTGF mice for breeding were kindly provided by Prof.

Fuchshofer (University Regensburg, Germany). Potential  $\beta$ B1-CTGF mice were screened by isolating genomic DNA from tail biopsies and testing for transgenic sequenced by PCR, using the following primer sequences: 5'-GGAAGTGCCAGCTCATCAGT-3' and 5'-GTGCGGGACAGAAACCTG-3'. 15 weeks old female and male mice were included in the study. All procedures concerning animals adhered to the ARVO statement for the use of animals in ophthalmic and vision research. All experiments involving animals were approved by the animal care committee of North Rhine-Westphalia, Germany. Mice were kept under environmentally controlled conditions with free access to chow and water.

### 2.2 | Measurement of IOP

Intraocular pressure of both eyes and both groups was measured at 5, 10 and 15 weeks ( $n = 6-10$  animals/group) using a rebound tonometer (TonoLab, Icare) as described previously.<sup>14,15</sup> For this procedure, mice were anaesthetized with a ketamine/xylazine cocktail (120/16 mg/kg). All measurements were performed by one examiner at the same time of the day. For each analysis, the mean of 10 measurements was calculated.

### 2.3 | Electroretinogram analyses

For electroretinogram (ERG) measurements, mice were dark adapted overnight. The retinal function was monitored in both eyes using full-field-flash electroretinography (HMsERG system, OcuScience LLC) after 15 weeks as described previously ( $n = 8$  animals/group).<sup>16,17</sup> Mice were anaesthetized with a ketamine/xylazine cocktail (120/16 mg/kg) and eyes were dilated with tropicamide (5%) and topically anaesthetized using conjuncain. Body temperature was maintained at 37°C with a feedback temperature controller (TC-1000; CWE Inc). Reference electrodes were placed subcutaneously below the right and left ear and a ground electrode was placed in the base of the tail. Contact lenses with silver thread recording electrodes were placed in the center of the cornea after application of methocel (Omni Vision). Before measurement, the electroretinography equipment was covered with a faraday cage. Scotopic flash ERGs were recorded at 0.1, 0.3, 1, 3, 10 and 25 cd.s/m<sup>2</sup>. For the light intensities of 0.1-3 cd.s/m<sup>2</sup>, four flashes were averaged and for 10 and 25 cd.s/m<sup>2</sup>, one flash was measured. The interstimulus interval was 10 seconds between flashes of the same light intensity. Signals obtained from the corneal surface were amplified, digitized, averaged and stored using commercial software (ERGView 4.380R; OcuScience LLC). A 50 Hz filtering of the data was applied before evaluating the amplitude of the a- and b-wave.

### 2.4 | Retinal ganglion cell counts via flatmounts

At 15 weeks, eyes were fixed in 4% paraformaldehyde for 1 hour and then prepared as flatmounts ( $n = 12$  eyes/group).<sup>18</sup> Briefly, flatmounts were blocked with 10% donkey serum in 0.5% Triton-X

in PBS for 90 minutes. Afterwards, they were incubated with the RGC marker Brn-3a (1:300, Santa Cruz) overnight. The corresponding secondary antibody, donkey anti-goat Alexa Fluor 488 (1:1000, Dianova), was added the next day for 2 hours. From each of the four flatmount arms, three photos were captured (central, middle, peripher) with an Axio Imager M2 fluorescence microscope (Zeiss). Brn-3a<sup>+</sup> cells were counted using ImageJ software (NIH).

## 2.5 | Immunohistology

In order to identify different retinal cell types, specific immunofluorescence antibodies were applied (n = 5-9 eyes/group, 6 sections/staining; Table 1).<sup>18</sup> Briefly, retina cross-sections were blocked with a solution containing 10%–20% donkey, 2%–3% BSA and/or goat serum and 0.1% Triton-X in PBS. For GFAP, 0.2% cold water fish gelatin was added. Primary antibodies were incubated

**TABLE 1** Primary and secondary antibodies used for immunohistochemistry

Primary antibodies			Secondary antibodies		
Antibody	Company	Dilution	Antibody	Company	Dilution
Anti-Brn-3a	Santa Cruz	1:100	Donkey anti-goat Alexa Fluor 488	Dianova	1:500
Anti-cleaved caspase 3	Sigma-Aldrich	1:300	Donkey anti-rabbit Alexa Fluor 555	Invitrogen	1:500
Anti-GFAP	Life Span Bioscience	1:2000	Goat anti-chicken Alexa Fluor 488	Molecular probes	1:1000
Anti-glutamine synthetase	Santa Cruz	1:250	Rabbit anti-goat Cy3	Jackson Immuno research	1:2000
Anti-opsin	Millipore	1:1200	Donkey anti-rabbit Alexa Fluor 555	Invitrogen	1:500
Anti-PKC $\alpha$	Santa Cruz	1:300	Goat anti-mouse Alexa Fluor 488	Invitrogen	1:500
Anti-rhodopsin	Abcam	1:400	Goat anti-mouse Alexa Fluor 488	Invitrogen	1:500
Anti-vimentin	Sigma-Aldrich	1:100	1. Biotinylated anti-goat IgG	Vector laboratories	1:500
			2. Streptavidin Alexa Fluor 555	Life technologies	1:1000

**TABLE 2** Adjustments of ImageJ macro for area analysis. The background subtraction as well as the lower and the upper thresholds are listed

Protein	Background subtraction (pixel)	Lower threshold	Upper threshold
GFAP	50	19.19	158.58
Glutamine synthetase	50	12.62	252.62
Recoverin	50	9.95	264
Rhodopsin	50	9.02	265
Vimentin	20	20.31	84.81

**TABLE 3** Sequences of oligonucleotides. The listed oligonucleotide pairs were used in quantitative real-time PCR experiments, while *B-actin* and *Cyclophilin* served as reference genes. The predicted amplicon sizes are given

Gene	Forward (F) and reverse (R) oligonucleotides	GenBank acc. no.	Amplicon size
<i>B-actin</i> -F <i>B-actin</i> -R	ctaaggccaacctgaaag accagaggcatacagggaca	NM_007393.5	104 bp
<i>Cyclophilin</i> -F <i>Cyclophilin</i> -R	ttctcataaccacaagtcaagacc tccacctcgtaccacatc	M60456.1	95 bp
<i>Gfap</i> -F <i>Gfap</i> -R	acagactttctccaactccag cctctgacacggatttgggt	NM_010277.3	63 bp
<i>Opsin</i> -F <i>Opsin</i> -R	ccgctatctgaagatctgttatctg tgccaggcagatgtaggc	AY318865.1	73 bp
<i>Pkca</i> -F <i>Pkca</i> -R	caagggatgaaatgtgacacc cctctctgtgtgatccattc	NM_011101.3	96 bp
<i>Pou4f1</i> -F <i>Pou4f1</i> -R	ctccctgagcacaagtacc ctggcgaagaggttctc	AY706205.1	98 bp
<i>Recoverin</i> -F <i>Recoverin</i> -R	caatgggaccatcagcaaa cctaggcttgatcatttga	NM_009038.2	71 bp
<i>Rhodopsin</i> -F <i>Rhodopsin</i> -R	tgtgtcttcacctggatcat gaacattgcatgccctcag	NM_145383.1	90 bp

Abbreviations: F, forward; R, reverse; acc. no, accession number; bp, base pair.

at room temperature overnight. Incubation using corresponding secondary antibodies was performed for 1 hour on the next day. Nuclear staining with 4',6 diamidino-2-phenylindole (DAPI, Serva Electrophoresis) was included to facilitate the orientation on the slides. Negative controls were performed by using secondary antibodies only.

## 2.6 | Histological examination

All photographs were taken using a fluorescence microscope (Axio Imager M1 or M2). Two photos of the peripheral and two of the central part of each section were captured. The images were transferred to Corel Paint Shop Pro (V13, Corel Corporation) and equal excerpts were cut out.<sup>19</sup> Afterwards, Brn-3a<sup>+</sup>, PKC $\alpha$ <sup>+</sup> and opsin<sup>+</sup> cells were counted using ImageJ software. Regarding GFAP, glutamine synthetase, vimentin, rhodopsin and recoverin, area analyses were performed using an ImageJ macro.<sup>19,20</sup> Briefly, images were transformed into grayscale. To minimize interference with background labeling, a defined rolling ball radius was subtracted (Table 2). Then, for each picture, a suitable lower threshold was set. The ideal threshold was obtained when the grayscale picture and the original one corresponded (Table 2). Afterwards, the mean value of the lower threshold was calculated, and this number was used for final analysis. The percentage of the labelled area was measured between these defined thresholds.

## 2.7 | Quantitative real-time PCR

Both retinæ of each animal (five animals/group) were pooled for RNA preparation and cDNA synthesis as previously described.<sup>18,21</sup> The designed oligonucleotides for Quantitative real-time PCR (qRT-PCR) are shown in Table 3. *B-actin* and *Cyclophilin* served as reference genes. The qRT-PCR was performed using DyNAmo Flash SYBR Green (Thermo Scientific) on the PikoReal qRT-PCR Cycler (Thermo Scientific).<sup>17,22</sup>


## 2.8 | Statistics

Intraocular pressure, ERG, and immunohistological data are presented as mean  $\pm$  SEM. The  $\beta$ B1-CTGF animals were compared to the WT group via two-tailed Student's *t* test using Statistica Software (Version 13, Dell). Regarding qRT-PCR, the relative expression values are presented as median $\pm$ quartile+minimum/maximum and were assessed via Pair Wise Fixed Reallocation Randomisation Test<sup>©</sup> using REST<sup>©</sup> software (Qiagen).<sup>18,21,23,24</sup> *P*-values below 0.05 were considered statistically significant, \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001.

## 3 | RESULTS

### 3.1 | Increase of IOP

Intraocular pressure was measured after 5, 10 and 15 weeks (Figure 1A). We could not measure significant changes in the IOP between  $\beta$ B1-CTGF and WT animals after 5 weeks ( $\beta$ B1-CTGF:



**FIGURE 1** (A), At 5, 10 and 15 wk, intraocular pressure (IOP) was measured in  $\beta$ B1-CTGF and wildtype (WT) animals. No changes regarding the IOP were notable in both groups after 5 and 10 wk ( $P > 0.05$ ). At 15 wk, a significantly increased IOP was observed in the  $\beta$ B1-CTGF group ( $P < 0.001$ ). (B), After 15 wk, electroretinogram (ERG) measurements were performed. The a-wave amplitude of the  $\beta$ B1-CTGF animals was significantly decreased at a light intensity of 0.1 cd.s/m<sup>2</sup> ( $P = 0.004$ ) and from 3 to 25 cd.s/m<sup>2</sup> ( $P < 0.01$ ). (C), Also, a significantly diminished b-wave amplitude was noted in the  $\beta$ B1-CTGF group compared to WT at all light intensities ( $P < 0.01$ ). Values are mean  $\pm$  SEM. \*\* $P < 0.01$ , \*\*\* $P < 0.001$ . IOP:  $n = 6$ -10 animals/group; ERG:  $n = 8$  animals/group

10.69  $\pm$  1.13 mm Hg; WT: 9.57  $\pm$  0.49 mm Hg;  $P = 0.3$ ) and 10 weeks ( $\beta$ B1-CTGF: 10.28  $\pm$  0.60 mm Hg; WT: 10.46  $\pm$  0.25 mm Hg;  $P = 0.8$ ). At 15 weeks, a significantly increased IOP could be observed in  $\beta$ B1-CTGF animals (17.49  $\pm$  1.09 mm Hg) compared to the WT littermates (11.09  $\pm$  0.20 mm Hg;  $P < 0.001$ ).

### 3.2 | Decrease of retinal function

At 15 weeks, ERG analyses were performed and all results of the a- and b-wave amplitudes are shown in Table 4. The a-wave amplitude represents the electrical output of the photoreceptors. At 0.1 cd.s/m<sup>2</sup>, we noted a significant decrease of the a-wave amplitude in  $\beta$ B1-CTGF retinæ compared to control ( $P = 0.004$ ). No changes were

**TABLE 4** Summary of electroretinogram results. For all light intensities, the mean a- and b-wave amplitudes of wildtype (WT) and  $\beta$ B1-CTGF animals and the respective p-values are shown

Light intensity	A-wave amplitude [ $\mu$ V]			B-wave amplitude [ $\mu$ V]		
	WT	$\beta$ B1-CTGF	P-value	WT	$\beta$ B1-CTGF	P-value
0.1 cd.s/m <sup>2</sup>	96.98 $\pm$ 8.27	52.90 $\pm$ 9.91	<b>0.004</b>	404.94 $\pm$ 14.95	238.81 $\pm$ 34.89	<b>&lt;0.001</b>
0.3 cd.s/m <sup>2</sup>	127.66 $\pm$ 10.06	94.09 $\pm$ 20.24	0.2	521.60 $\pm$ 20.87	279.91 $\pm$ 47.97	<b>&lt;0.001</b>
1 cd.s/m <sup>2</sup>	157.30 $\pm$ 8.56	118.01 $\pm$ 36.92	0.3	515.39 $\pm$ 23.42	304.58 $\pm$ 58.68	<b>0.004</b>
3 cd.s/m <sup>2</sup>	186.71 $\pm$ 9.32	116.95 $\pm$ 22.14	<b>0.01</b>	530.76 $\pm$ 15.28	295.24 $\pm$ 63.20	<b>0.002</b>
10 cd.s/m <sup>2</sup>	226.40 $\pm$ 9.99	142.20 $\pm$ 27.09	<b>0.01</b>	589.04 $\pm$ 22.62	330.59 $\pm$ 60.13	<b>0.001</b>
25 cd.s/m <sup>2</sup>	233.45 $\pm$ 12.05	143.29 $\pm$ 27.52	<b>0.009</b>	600.70 $\pm$ 25.79	365.19 $\pm$ 62.68	<b>0.003</b>

Significant P values are marked in bold.


noted at the light intensities of 0.3 cd.s/m<sup>2</sup> ( $P = 0.2$ ) and 1 cd.s/m<sup>2</sup> ( $P = 0.3$ ). However, a significantly reduced a-wave response was observed in  $\beta$ B1-CTGF animals compared to WT ( $P = 0.01$ ) at 3 cd.s/m<sup>2</sup>. Also, at a light intensity of 10 cd.s/m<sup>2</sup>, a decreased a-wave amplitude was observed ( $P = 0.01$ ). This reduction was also noted in  $\beta$ B1-CTGF animals compared to WT ( $P = 0.009$ ) at 25 cd.s/m<sup>2</sup> (Figure 1B).

The b-wave amplitude represents the output of the inner nuclear layers. At the light intensities of 0.1 cd.s/m<sup>2</sup> and 0.3 cd.s/m<sup>2</sup>, a significantly reduced b-wave amplitude was observed in  $\beta$ B1-CTGF retinae compared to WT ( $P < 0.001$ ). This decrease could also be shown at 1 cd.s/m<sup>2</sup> ( $P = 0.004$ ). At a light intensity of 3 cd.s/m<sup>2</sup>, a decreased

b-wave amplitude is notable in  $\beta$ B1-CTGF animals compared to WT ( $P = 0.002$ ). The b-wave response was significantly reduced in  $\beta$ B1-CTGF retinae compared to WT ( $P = 0.001$ ) at 10 cd.s/m<sup>2</sup>. Also, at 25 cd.s/m<sup>2</sup>, the b-wave amplitude was significantly decreased in  $\beta$ B1-CTGF animals compared to WT animals ( $P = 0.003$ ) (Figure 1C).

### 3.3 | Loss of retinal ganglion cells

To evaluate a possible alteration in the number of RGCs, flatmounts were stained with an antibody against Brn-3a<sup>18</sup> (Figure 2A). Additionally, qRT-PCR analyses were performed regarding the



**FIGURE 2** (A), Flatmounts of both groups were labelled with the retinal ganglion cell marker Brn-3a (green) after 15 wk. (B),  $\beta$ B1-CTGF retinae revealed a significant loss of Brn-3a<sup>+</sup> cells compared to wildtype ( $P = 0.02$ ). (C), QRT-PCR analyses showed a down-regulation of *Pou4f1* mRNA levels in  $\beta$ B1-CTGF animals ( $P = 0.02$ ). Values are mean  $\pm$  SEM for immunohistology and median $\pm$ quartile+maximum/minimum for qRT-PCR. Scale bar: 20  $\mu$ m. \* $P < 0.05$ . Flatmounts:  $n = 12$  eyes/group; qRT-PCR:  $n = 5$  animals/group

mRNA level of *Pou4f1* (Figure 2C). Significantly fewer Brn-3a<sup>+</sup> cells were noted in  $\beta$ B1-CTGF animals ( $3399.39 \pm 114.57$  cells/mm<sup>2</sup>) in comparison to WT ( $4186.92 \pm 282.94$  cells/mm<sup>2</sup>;  $P = 0.02$ ) after 15 weeks (Figure 2B). Furthermore, a significant down-regulation was observed in *Pou4f1* mRNA levels at this age (0.40-fold;  $P = 0.02$ ).

To confirm the loss of RGCs, cross-sections were labeled with anti-Brn-3a. To detect a possible apoptosis of RGCs, co-staining with an antibody against cleaved caspase 3 was performed (Figure 3A). We noted a loss of RGCs in  $\beta$ B1-CTGF retinæ ( $25.50 \pm 2.80$  cells/mm) compared to WT animals ( $43.59 \pm 3.03$  cells/mm;  $P = 0.0005$ ; Figure 3B). Additionally, significantly more cleaved caspase 3<sup>+</sup> RGCs were observed in the  $\beta$ B1-CTGF group ( $15.41 \pm 1.78\%$ ) in comparison to WT retinæ ( $6.63 \pm 1.60\%$ ;  $P = 0.002$ ; Figure 3C).


### 3.4 | Macroglia activation

A possible macrogliosis was investigated by labeling retinæ against anti-GFAP, anti-vimentin and anti-glutamine synthetase (Müller glia and astrocytes; Figure 4A). Furthermore, the mRNA expression levels of *Gfap* was evaluated via qRT-PCR (Figure 4C). The GFAP area analysis showed a slight trend to more GFAP signal in  $\beta$ B1-CTGF mice ( $3.36 \pm 0.41$  area [%]/section) compared to WT ( $2.39 \pm 0.28$  area [%]/section;  $P = 0.09$ ; Figure 4B). However, qRT-PCR analyses

revealed a significant up-regulation of *Gfap* expression levels in the  $\beta$ B1-CTGF retinæ compared to WT (2.2-fold;  $P = 0.02$ ; Figure 4C). Furthermore, a trend towards more vimentin<sup>+</sup> area was observed in  $\beta$ B1-CTGF retinæ (WT:  $5.95 \pm 0.93$  area [%]/section;  $\beta$ B1-CTGF:  $9.76 \pm 1.67$  area [%]/section;  $P = 0.08$ ; Figure 4D). Significantly more glutamine synthetase signal was noted in  $\beta$ B1-CTGF animals ( $11.89 \pm 1.17$  area [%]/section) in comparison to WT ( $7.15 \pm 1.47$  area [%]/section;  $P = 0.04$ ; Figure 4E).

### 3.5 | Decrease in cone bipolar cells

To evaluate the number of bipolar cells, retinæ were labelled with anti-PKC $\alpha$  (rod bipolar cells) and anti-recoverin (cone bipolar cells; Figure 5A). Additionally, qRT-PCR analyses were performed regarding the mRNA levels of *Pkca* and *Recoverin* (Figure 5C,E). We noted a significantly smaller recoverin<sup>+</sup> signal area in retinæ of the  $\beta$ B1-CTGF group ( $13.02 \pm 1.47$  area [%]/section) in comparison with WT mice ( $21.15 \pm 1.74$  area [%]/section;  $P = 0.004$ ; Figure 5B). Furthermore, the qRT-PCR analyses showed a significant down-regulation of *Recoverin* mRNA levels in  $\beta$ B1-CTGF animals (0.37-fold expression;  $P < 0.001$ ; Figure 5C). Staining with PKC $\alpha$  revealed no changes in the  $\beta$ B1-CTGF group ( $17.36 \pm 0.82$  cells/mm) compared to WT ( $16.63 \pm 0.92$  cells/mm;  $P > 0.05$ ; Figure 5D). Also, we noted no



**FIGURE 3** (A), Retinal cross-sections were stained against Brn-3a (green) and the apoptosis marker cleaved caspase 3 (red) at 15 wk. Cell nuclei were visualized with DAPI (blue). (B), The number of Brn-3a<sup>+</sup> cells was significantly decreased in the  $\beta$ B1-CTGF mice compared to wildtype (WT) mice ( $P < 0.001$ ). (C), Additionally, significantly more cleaved caspase 3<sup>+</sup> retinal ganglion cells were revealed in  $\beta$ B1-CTGF mice compared to WT animals ( $P = 0.002$ ). GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer. Values are mean  $\pm$  SEM. Scale bar: 20  $\mu$ m. \*\* $P < 0.01$ , \*\*\* $P < 0.001$ . N = 9 eyes/group


changes in *Pkcα* mRNA levels in  $\beta$ B1-CTGF retinæ (1.1-fold expression;  $P = 0.6$ ; Figure 5E).


### 3.6 | Effects on photoreceptors

At 15 weeks, possible alterations regarding the photoreceptors was investigated. Therefore, L-cones were labelled with anti-opsin and rods were visualized with anti-rhodopsin (Figure 6A). Furthermore, *Rhodopsin* and *Opsin* mRNA expression levels were analysed via qRT-PCR (Figure 6C,E). The density of the rhodopsin<sup>+</sup> area was comparable in both groups (WT:  $9.43 \pm 0.88$  area [%]/section;  $\beta$ B1-CTGF:  $8.51 \pm 0.44$  area [%]/section;  $P > 0.05$ ; Figure 6B). However, a significant down-regulation of *Rhodopsin* mRNA levels was noted in  $\beta$ B1-CTGF animals (0.42-fold expression;  $P = 0.003$ ; Figure 6C). No changes were observed in the number of opsin<sup>+</sup> cells in  $\beta$ B1-CTGF retinæ ( $33.38 \pm 3.42$  cells/mm,  $P > 0.05$ ) compared to WT ( $31.28 \pm 1.51$  cells/mm; Figure 6D). The qRT-PCR analyses revealed a significant down-regulation of *Opsin* mRNA levels in  $\beta$ B1-CTGF animals (0.41-fold expression;  $P = 0.03$ ; Figure 6E).


## 4 | DISCUSSION

The pathomechanisms leading to glaucoma are still not known precisely. However, an elevated IOP has been consistently associated with the prevalence<sup>25-28</sup> and incidence<sup>29-31</sup> of open-angle glaucoma.<sup>1</sup> In most western countries, approximately half of the patients with manifest glaucoma are not diagnosed.<sup>1,32,33</sup> To improve both the treatment and the diagnosis of glaucoma patients, it is necessary to have appropriate models. The  $\beta$ B1-CTGF mouse seems to be a promising tool to analyze mechanisms in POAG. In 2012, Junglas et al reported that the overexpression of CTGF led to an increased IOP accompanied with a progressive loss of optic nerve axons.<sup>12</sup> In this study, the transgenic  $\beta$ B1-CTGF mice also developed an elevated IOP after 15 weeks. This is diverging to previous results, where an increased IOP was noted already after 1 month.<sup>12</sup> These varieties could be explained by different environments and mouse strains. In the original paper, the mice were analysed in a mixed background of FVBN/CD1 in the first generation, whereas the mice used in this study were in a pure CD1 background. The CD1-strain is an out-bred





**FIGURE 5** (A), Cone bipolar cells were evaluated by using recoverin (red) and rod bipolar cells using PKC $\alpha$  staining (green). Cell nuclei were labeled with DAPI (blue). (B), The analyses of the recoverin<sup>+</sup> area revealed a significantly decreased staining area in  $\beta$ B1-CTGF animals ( $P = 0.004$ ). (C), The analyses of *Recoverin* mRNA expression showed a significant down-regulation in the  $\beta$ B1-CTGF group ( $P < 0.001$ ). (D), PKC $\alpha$ <sup>+</sup> cells were not altered in  $\beta$ B1-CTGF retinæ compared to wildtype (WT) ( $P > 0.05$ ). (E), The mRNA expression levels of *Pkc $\alpha$*  revealed no changes in  $\beta$ B1-CTGF retinæ ( $P = 0.6$ ). INL, inner nuclear layer; ONL, outer nuclear layer; OPL, outer plexiform layer. Values are mean  $\pm$  SEM for immunohistology and median $\pm$ quartile+maximum/minimum for qRT-PCR. Scale bar: 20  $\mu$ m. \*\* $P < 0.01$ , \*\*\* $P < 0.001$ . Immunohistology:  $n = 7$  eyes/group; qRT-PCR:  $n = 5$  animals/group




strain with a higher genetic variability. Furthermore, it is described that the same experiment, performed in two laboratories, can lead to a discrepancy in the results.<sup>34,35</sup> Nevertheless, we could constantly

measure an increase of the IOP in  $\beta$ B1-CTGF mice. In this study, we focused on IOP-dependent damage in the retina. Simultaneously to the observed IOP elevation, we could also detect an apoptotic loss



**FIGURE 6** (A), Rhodopsin (rods, green) and opsin (L-cones, red) staining of retinal sections was performed to evaluate photoreceptors. DAPI was added to visualize cell nuclei (blue). (B), Comparable rhodopsin<sup>+</sup> areas were detected in both groups ( $P > 0.05$ ). (C), However, qRT-PCR analyses revealed a significant down-regulation of *Rhodopsin* mRNA expression levels in  $\beta$ B1-CTGF retinæ ( $P = 0.003$ ). (D), The number of opsin<sup>+</sup> cells remained unaltered in  $\beta$ B1-CTGF animals compared to wildtype (WT) ( $P > 0.05$ ). (E), The mRNA expression levels of *Opsin* were significantly down-regulated in  $\beta$ B1-CTGF retinæ ( $P = 0.03$ ). ONL, outer plexiform layer; OS, outer segment. Values are mean  $\pm$  SEM for immunohistology and median $\pm$ quartile+maximum/minimum for qRT-PCR. Scale bar: 20  $\mu$ m. \* $P < 0.05$ , \*\* $P < 0.01$ . Immunohistology:  $n = 7$  eyes/group; qRT-PCR:  $n = 5$  animals/group



of RGCs at 15 weeks. Based on the results of the initial study, we conclude that the IOP dependent axon loss in the optic nerve leads than to a consecutive loss of RGCs. The time course of progression in the  $\beta$ B1-CTGF mice would be similar to the development of glaucoma disease in patients.<sup>1,36</sup>

The majority of retinal diseases are associated with reactive gliosis.<sup>37-39</sup> The astrocytes and Müller glia cells become reactive during

the pathogenesis of glaucoma, characterized by morphologic alterations and expression changes.<sup>40-42</sup> We found that the observed loss of RGC cells is accompanied by changes of the macroglia cells in the retinæ of the  $\beta$ B1-CTGF mice. The immunohistological analysis showed a slight increase of astrocytic markers like GFAP and vimentin, but we found a profound increase of GFAP mRNA in the  $\beta$ B1-CTGF mice. We assume that the changes could be the start of a

remodelling process in the retinal astrocytes based on the IOP and the RGC loss. It is known that astrocytes of the optic nerve head respond strongly to glaucomatous damage.<sup>43</sup> In retinal diseases, the induction of GFAP in Müller cells is an early and very sensitive marker for reactive Müller cells, which is often accompanied by an increased expression of glutamine synthetase.<sup>44</sup> Accordingly, in the eyes of human donors suffering from glaucoma, an increased expression of GFAP in Müller cells has been detected.<sup>45</sup> In our study, the Müller glial cells showed a GFAP positive signal in the  $\beta$ B1-CTGF mice in comparison to the WT littermates. As the Müller glial signal of the GFAP staining had an overlap with the signal of the astrocytes it is rather difficult to quantify the differences. To overcome this problem, we stained against glutamine synthetase in both groups. The Müller glial cells had a significant enhanced signal for glutamine synthetase, which emphasize a reactive state of the Müller glial cells. The enhanced reactivity of Müller glial cells could be a response to the IOP induced RGC loss and can mediate both protective as well as detrimental effects on retinal neurons.<sup>44</sup>

To characterize the  $\beta$ B1-CTGF model more precisely, we additionally investigated whether an increased IOP could affect also other retinal layers. In previous studies, the induction of OHT in mice of the albino Swiss strain caused a reduced recoverin immunoreactivity and the number of PKC $\alpha$ <sup>+</sup> rod bipolar cells was diminished.<sup>46</sup> Similar results were observed in a rat model after IOP elevation, were a decrease of rod bipolar cells was reported 5 weeks after IOP elevation.<sup>47</sup> In our study, we could only observe a diminished cone bipolar cell signal at 15 weeks of age in the retinae of the  $\beta$ B1-CTGF in comparison to their WT littermates. The different results regarding the rod bipolar cells could be explained by the different experimentally and genetically mechanisms causing the increased IOP. In the  $\beta$ B1-CTGF mouse, cone bipolar cells seem to be more sensitive to IOP changes. Nevertheless, ERG data from our study suggest a functional loss of inner nuclear cells and photoreceptors in  $\beta$ B1-CTGF animals. In glaucoma patients, ERG measurements revealed a degeneration of photoreceptor cells in late stages of glaucoma.<sup>48,49</sup> Also after laser coagulation in rats, a secondary loss of cones could be observed.<sup>50</sup> In aged DBA2/J mice, the a-wave amplitude was decreased, pointing towards an impairment of photoreceptors.<sup>51</sup>

In summary, elevated IOP is accompanied by apoptotic RGC loss and reactive gliosis in the  $\beta$ B1-CTGF mice. We therefore conclude that the  $\beta$ B1-CTGF mouse model can be used to study pathomechanisms occurring in POAG.

## ACKNOWLEDGEMENTS

This study was supported by FoRUM (Ruhr-University Bochum), Deutsche Forschungsgemeinschaft (FU734/4-1), and Ernst und Berta Grimmke foundation (Germany). We acknowledge support by the DFG Open Access Publication Funds of the Ruhr-University Bochum.

## CONFLICT OF INTEREST

The authors confirm that there are no conflict of interest.

## AUTHOR CONTRIBUTIONS

SR, DK, FF, MW and CV performed the research; SR, DK, and MW analysed the data; RF and SCJ designed the research study; SR wrote the paper; HBD, RF, and SCJ reviewed the manuscript.

## ORCID

Stephanie C. Joachim  <https://orcid.org/0000-0001-7056-0829>

## REFERENCES

1. European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 2: Classification and terminology. *Br J Ophthalmol*. 2017;101:73–127.
2. Kerrigan-Baumrind LA, Quigley HA, Pease ME, Kerrigan DF, Mitchell RS. Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons. *Invest Ophthalmol Vis Sci*. 2000;41:741–748.
3. Morrison JC, Moore CG, Deppmeier LM, Gold BG, Meshul CK, Johnson EC. A rat model of chronic pressure-induced optic nerve damage. *Exp Eye Res*. 1997;64:85–96.
4. Levkovitch-Verbin H, Quigley HA, Martin KR, Valenta D, Baumrind LA, Pease ME. Translimbal laser photocoagulation to the trabecular meshwork as a model of glaucoma in rats. *Invest Ophthalmol Vis Sci*. 2002;43:402–410.
5. Shareef SR, Garcia-Valenzuela E, Salierno A, Walsh J, Sharma SC. Chronic ocular hypertension following episcleral venous occlusion in rats. *Exp Eye Res*. 1995;61:379–382.
6. Sappington RM, Carlson BJ, Crish SD, Calkins DJ. The microbead occlusion model: a paradigm for induced ocular hypertension in rats and mice. *Invest Ophthalmol Vis Sci*. 2010;51:207–216.
7. John SW, Smith RS, Savinova OV, et al. Essential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice. *Invest Ophthalmol Vis Sci*. 1998;39:951–962.
8. Libby RT, Anderson MG, Pang IH, et al. Inherited glaucoma in DBA/2J mice: pertinent disease features for studying the neurodegeneration. *Vis Neurosci*. 2005;22:637–648.
9. Wang J, Dong Y. Characterization of intraocular pressure pattern and changes of retinal ganglion cells in DBA2J glaucoma mice. *Int J Ophthalmol*. 2016;9:211–217.
10. Anderson MG, Libby RT, Mao M, et al. Genetic context determines susceptibility to intraocular pressure elevation in a mouse pigmented glaucoma. *BMC Biol*. 2006;4:20.
11. Libby RT, Gould DB, Anderson MG, John SW. Complex genetics of glaucoma susceptibility. *Annu Rev Genomics Hum Genet*. 2005;6:15–44.
12. Junglas B, Kuespert S, Seleem AA, et al. Connective tissue growth factor causes glaucoma by modifying the actin cytoskeleton of the trabecular meshwork. *Am J Pathol*. 2012;180:2386–2403.
13. Ohlmann A, Seitz R, Braunger B, Seitz D, Bosl MR, Tamm ER. Norrin promotes vascular regrowth after oxygen-induced retinal vessel loss and suppresses retinopathy in mice. *J Neurosci*. 2010;30:183–193.
14. Noristani R, Kuehn S, Stute G, et al. Retinal and optic nerve damage is associated with early glial responses in an experimental autoimmune glaucoma model. *J Mol Neurosci*. 2016;58:470–482.
15. Joachim SC, Gramlich OW, Laspas P, et al. Retinal ganglion cell loss is accompanied by antibody depositions and increased levels of microglia after immunization with retinal antigens. *PLoS ONE*. 2012;7:e40616.
16. Schmid H, Renner M, Dick HB, Joachim SC. Loss of inner retinal neurons after retinal ischemia in rats. *Invest Ophthalmol Vis Sci*. 2014;55:2777–2787.

17. Wilmes AT, Reinehr S, Kuhn S, et al. Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model. *J Neuroinflammation*. 2018;15:183.
18. Reinehr S, Reinhard J, Gandej M, et al. Simultaneous complement response via lectin pathway in retina and optic nerve in an experimental autoimmune glaucoma model. *Front Cell Neurosci*. 2016;10:140.
19. Reinehr S, Kuehn S, Casola C, et al. HSP27 immunization reinforces All amacrine cell and synapse damage induced by S100 in an autoimmune glaucoma model. *Cell Tissue Res*. 2018;371:237-249.
20. Casola C, Reinehr S, Kuehn S, et al. Specific inner retinal layer cell damage in an autoimmune glaucoma model is induced by GDNF with or without HSP27. *Invest Ophthalmol Vis Sci*. 2016;57:3626-3639.
21. Reinhard J, Renner M, Wiemann S, et al. Ischemic injury leads to extracellular matrix alterations in retina and optic nerve. *Sci Rep*. 2017;7:43470.
22. Palmhof M, Lohmann S, Schulte D, et al. Fewer functional deficits and reduced cell death after ranibizumab treatment in a retinal ischemia model. *Int J Mol Sci*. 2018;19:1636. <https://doi.org/10.3390/ijms19061636>
23. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. *Nucleic Acids Res*. 2002;30:e36.
24. Reinehr S, Reinhard J, Wiemann S, et al. Early remodelling of the extracellular matrix proteins tenascin-C and phosphacan in retina and optic nerve of an experimental autoimmune glaucoma model. *J Cell Mol Med*. 2016;20:2122-2137.
25. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. *Ophthalmology*. 1992;99:1499-1504.
26. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. *JAMA*. 1991;266:369-374.
27. Dielemans I, Vingerling JR, Wolfs RC, Hofman A, Grobbee DE, de Jong PT. The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. *Ophthalmology*. 1994;101:1851-1855.
28. Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. *Surv Ophthalmol*. 2008;53(Suppl 1):S3-S10.
29. Czudowska MA, Ramdas WD, Wolfs RC, et al. Incidence of glaucomatous visual field loss: a ten-year follow-up from the Rotterdam study. *Ophthalmology*. 2010;117:1705-1712.
30. Nemesure B, Honkanen R, Hennis A, Wu SY, Leske MC. Barbados Eye Studies G. Incident open-angle glaucoma and intraocular pressure. *Ophthalmology*. 2007;114:1810-1815.
31. Le A, Mukesh BN, McCarty CA, Taylor HR. Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project. *Invest Ophthalmol Vis Sci*. 2003;44:3783-3789.
32. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. *Ophthalmology*. 1996;103:1661-1669.
33. Quigley HA, Jampel HD. How are glaucoma patients identified? *J Glaucoma*. 2003;12:451-455.
34. Crabbe JC, Wahlsten D, Dudek BC. Genetics of mouse behavior: interactions with laboratory environment. *Science*. 1999;284:1670-1672.
35. Wahlsten D, Bachmanov A, Finn DA, Crabbe JC. Stability of inbred mouse strain differences in behavior and brain size between laboratories and across decades. *Proc Natl Acad Sci USA*. 2006;103:16364-16369.
36. Open Angle Glaucoma - Diagnosis, Follow-up, and Treatment: A Systematic Literature Review. Stockholm. 2008.
37. Garcia M, Vecino E. Role of Muller glia in neuroprotection and regeneration in the retina. *Histol Histopathol*. 2003;18:1205-1218.
38. Bringmann A, Pannicke T, Grosche J, et al. Muller cells in the healthy and diseased retina. *Prog Retin Eye Res*. 2006;25:397-424.
39. Galan A, Dergham P, Escoll P, et al. Neuronal injury external to the retina rapidly activates retinal glia, followed by elevation of markers for cell cycle re-entry and death in retinal ganglion cells. *PLoS ONE*. 2014;9:e101349.
40. Hernandez MR. The optic nerve head in glaucoma: role of astrocytes in tissue remodeling. *Prog Retin Eye Res*. 2000;19:297-321.
41. Pena JD, Varela HJ, Ricard CS, Hernandez MR. Enhanced tenascin expression associated with reactive astrocytes in human optic nerve heads with primary open angle glaucoma. *Exp Eye Res*. 1999;68:29-40.
42. Wang X, Tay SS, Ng YK. An immunohistochemical study of neuronal and glial cell reactions in retinæ of rats with experimental glaucoma. *Exp Brain Res*. 2000;132:476-484.
43. Schneider M, Fuchshofer R. The role of astrocytes in optic nerve head fibrosis in glaucoma. *Exp Eye Res*. 2016;142:49-55.
44. Seitz R, Ohlmann A, Tamm ER. The role of Muller glia and microglia in glaucoma. *Cell Tissue Res*. 2013;353:339-345.
45. Tezel G, Wax MB. Glial modulation of retinal ganglion cell death in glaucoma. *J Glaucoma*. 2003;12:63-68.
46. Cuenca N, Pinilla I, Fernandez-Sanchez L, et al. Changes in the inner and outer retinal layers after acute increase of the intraocular pressure in adult albino Swiss mice. *Exp Eye Res*. 2010;91:273-285.
47. Hernandez M, Rodriguez FD, Sharma SC, Vecino E. Immunohistochemical changes in rat retinas at various time periods of elevated intraocular pressure. *Mol Vis*. 2009;15:2696-2709.
48. Nork TM, Ver Hoeve JN, Poulsen GL, et al. Swelling and loss of photoreceptors in chronic human and experimental glaucomas. *Arch Ophthalmol*. 2000;118:235-245.
49. Velten IM, Korth M, Horn FK. The a-wave of the dark adapted electroretinogram in glaucomas: are photoreceptors affected? *Br J Ophthalmol*. 2001;85:397-402.
50. Ortin-Martinez A, Salinas-Navarro M, Nadal-Nicolas FM, et al. Laser-induced ocular hypertension in adult rats does not affect non-RGC neurons in the ganglion cell layer but results in protracted severe loss of cone-photoreceptors. *Exp Eye Res*. 2015;132:17-33.
51. Heiduschka P, Julien S, Schuettauf F, Schnichels S. Loss of retinal function in aged DBA/2J mice - New insights into retinal neurodegeneration. *Exp Eye Res*. 2010;91:779-783.

**How to cite this article:** Reinehr S, Koch D, Weiss M, et al. Loss of retinal ganglion cells in a new genetic mouse model for primary open-angle glaucoma. *J Cell Mol Med*. 2019;23:5497-5507. <https://doi.org/10.1111/jcmm.14433>